Esophageal adenocarcinoma (EAC) is difficult to treat and carries a poor prognosis. Barrett’s esophagus, which develops from long-standing gastroesophageal reflux disease, is the only known precursor to EAC. Endoscopic eradication therapy is a major advancement in the treatment of dysplastic Barrett’s esophagus and early EAC; however, failure to eradicate disease and a high rate of recurrence with risk of progression currently remain unacceptably high with the use of acid suppressive medication for reflux. Herein, we describe the physiology of gastroesophageal reflux and review the current literature on endoscopic eradication therapy for Barrett’s esophagus. We summarize that antireflux surgery for reflux control as an adjunct to endoscopic eradication therapy may decrease the need for multiple endoscopic sessions (to achieve eradication), decrease the risk for recurrence/progression, and potentially decrease the need for surveillance.
CottonCCWolfWAOverholtBF, et al. Late recurrence of Barrett’s esophagus after complete eradication of intestinal metaplasia is rare: final report from ablation in intestinal metaplasia containing dysplasia trial. Gastroenterology. 2017;153(3):681-688.e2.
2.
KahnAShaheenNJIyerPG. Approach to the post-ablation Barrett’s esophagus patient. Am J Gastroenterol. 2020;115(6):823-831.
3.
O’ConnellKVelanovichV. Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus. Surg Endosc. 2011;25(3):830-834.
4.
TanMCKanthasamyKAYehAG, et al. Factors associated with recurrence of Barrett’s esophagus after radiofrequency ablation. Clin Gastroenterol Hepatol. 2019;17(1):65-72.e5.
5.
ShaheenNJOverholtBFSamplinerRE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141(2):460-468.
6.
GrossSASharmaP. Recurrence of cancer after endoscopic ablation of Barrett’s esophagus: is the elephant in the room. . .persistent ongoing reflux?Dig Dis Sci. 2014; 59(7):1354-1355.
MasudaTMittalSKKovacsBCsucskaMBremnerRM. Simple manometric index for comprehensive esophagogastric junction barrier competency against gastroesophageal reflux. J Am Coll Surg. 2020;230(5):744-755.e3.
9.
AndriciJTioMCoxMREslickGD. Hiatal hernia and the risk of Barrett’s esophagus. J Gastroenterol Hepatol. 2013;28(3):415-31.
10.
AkimotoSSinghalSMasudaTMittalSK. Classification for esophagogastric junction (EGJ) complex based on physiology. Dis Esophagus. 2017;30(6):1-6.
SteinHJDeMeesterTRNaspettiRJamiesonJPerryRE. Three-dimensional imaging of the lower esophageal sphincter in gastroesophageal reflux disease. Ann Surg. 1991;214(4):374-383; discussion 383-4.
13.
SchoppmannSFKristoIRieglerM. Does anti-reflux surgery disrupt the pathway of Barrett’s esophagus progression to cancer?Transl Gastroenterol Hepatol. 2018;3:101.
14.
GalmicheJP. Impedance-pH monitoring in proton pump inhibitor resistant patients: ready for clinical application?Gut. 2006;55(10):1379-1381.
15.
MalfertheinerPNoconMViethM, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care–the ProGERD study. Aliment Pharmacol Ther. 2012;35(1):154-164.
16.
MinerPJr.KatzPOChenYSostekM. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616-2620.
17.
VelaMFCamacho-LobatoLSrinivasanRTutuianRKatzPOCastellDO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120(7):1599-1606.
18.
GencoASoricelliECasellaG, et al. Gastroesophageal reflux disease and Barrett’s esophagus after laparoscopic sleeve gastrectomy: a possible, underestimated long-term complication. Surg Obes Relat Dis. 2017;13(4):568-574.
19.
SebastianelliLBenoisMVanbiervlietG, et al. Systematic endoscopy 5 years after sleeve gastrectomy results in a high rate of Barrett’s esophagus: results of a multicenter study. Obes Surg. 2019;29(5):1462-1469.
20.
MartinucciIde BortoliNGiacchinoM, et al. Esophageal motility abnormalities in gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014;5(2):86-96.
21.
KrishnamoorthiRSinghSRagunathanK, et al. Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy. Gastrointest Endosc. 2016;83(6):1090-1106.e3.
22.
OrmanESLiNShaheenNJ. Efficacy and durability of radiofrequency ablation for Barrett’s esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(10):1245-1255.
23.
KahnAAl-QaisiMKommineniVT, et al. Longitudinal outcomes of radiofrequency ablation versus surveillance endoscopy for Barrett’s esophagus with low-grade dysplasia. Dis Esophagus. 2018;31(4): dox120.
24.
PeerallyMFBhandariPRagunathK, et al. Radiofrequency ablation compared with argon plasma coagulation after endoscopic resection of high-grade dysplasia or stage T1 adenocarcinoma in Barrett’s esophagus: a randomized pilot study (BRIDE). Gastrointest Endosc. 2019;89(4):680-689.
25.
PouwREKlaverEPhoaKN, et al. Radiofrequency ablation for low-grade dysplasia in Barrett’s esophagus: long-term outcome of a randomized trial. Gastrointest Endosc. 2020;92(3):569-574.
26.
LuckettTAllamneniCCowleyKEickJGullickAPeterS. Length of Barrett’s segment predicts failure of eradication in radiofrequency ablation for Barrett’s esophagus: a retrospective cohort study. BMC Gastroenterol. 2018;18(1):67.
27.
Al NatourRHCatanzaroAZolotarevskyEDeBenedetATGunaratnamNT. Endoscopic therapy for Barrett’s high grade dysplasia and intramucosal esophageal cancer is effective in community clinical practice by advanced endoscopists following multidisciplinary approach. Dis Esophagus. 2018;31(1):1-6.
28.
PhoaKNvan VilsterenFGWeustenBL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209-1217.
29.
SenguptaNKetwarooGABakDM, et al. Salvage cryotherapy after failed radiofrequency ablation for Barrett’s esophagus-related dysplasia is safe and effective. Gastrointest Endosc. 2015;82(3):443-448.
30.
HaidryRJLipmanGBanksMR, et al. Comparing outcome of radiofrequency ablation in Barrett’s with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry. Endoscopy. 2015;47(11):980-987.
31.
GanzRAOverholtBFSharmaVK, et al. Circumferential ablation of Barrett’s esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc. 2008;68(1):35-40.
32.
OrmanESKimHPBulsiewiczWJ, et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett’s esophagus with radiofrequency ablation. Am J Gastroenterol. 2013;108(2):187-195; quiz 196.
33.
GuthikondaACottonCCMadanickRD, et al. Clinical outcomes following recurrence of intestinal metaplasia after successful treatment of Barrett’s esophagus with radiofrequency ablation. Am J Gastroenterol. 2017;112(1):87-94.
34.
KomanduriSKahrilasPJKrishnanK, et al. Recurrence of Barrett’s esophagus is rare following endoscopic eradication therapy coupled with effective reflux control. Am J Gastroenterol. 2017;112(4):556-566.
35.
YasudaKChoiSENishiokaNS, et al. Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett’s esophagus. Dig Dis Sci. 2014;59(7): 1560-1566.
36.
Guarner-ArgenteCBuoncristianoTFurthEEFalkGWGinsbergGG. Long-term outcomes of patients with Barrett’s esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc. 2013;77(2):190-199.
37.
SkrobićOSimićARadovanovićNIvanovićNMicevMPeškoP. Significance of Nissen fundoplication after endoscopic radiofrequency ablation of Barrett’s esophagus. Surg Endosc. 2016;30(9):3802-3807.
38.
KrishnanKPandolfinoJEKahrilasPJKeeferLBorisLKomanduriS. Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology. 2012;143(3):576-581.
39.
SamiSSRavindranAKahnA, et al. Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study. Gut. 2019; 68(8):1379-1385.
40.
KorstRJSantana-JosephSRutledgeJR, et al. Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett’s esophagus. J Thorac Cardiovasc Surg. 2013;145(6):1529-1534.
41.
WaniSHanSKushnirV, et al. Recurrence is rare following complete eradication of intestinal metaplasia in patients with Barrett’s esophagus and peaks at 18 months. Clin Gastroenterol Hepatol. 2020;18(11):2609-2617.e2.
42.
FerrarisRFracchiaMFotiM, et al. Barrett’s oesophagus: long-term follow-up after complete ablation with argon plasma coagulation and the factors that determine its recurrence. Aliment Pharmacol Ther. 2007;25(7):835-840.
43.
MilashkaMCalommeAVan LaethemJL, et al. Sixteen-year follow-up of Barrett’s esophagus, endoscopically treated with argon plasma coagulation. United European Gastroenterol J. 2014;2(5):367-373.
44.
HubbardNVelanovichV. Endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus in patients with fundoplications. Surg Endosc. 2007;21(4):625-628.
45.
JohnsonCSLouieBEWilleA, et al. The durability of endoscopic therapy for treatment of Barrett’s metaplasia, dysplasia, and mucosal cancer after Nissen fundoplication. J Gastrointest Surg. 2015;19(5):799-805.
46.
PuchkovKVKhabarovaEVTishchenkoES. Two-stage treatment of Barrett’s esophagus [Radikal’noe dvukhetapnoe lechenie bol’nykh s pishchevodom Barretta]. Khirurgiia (Mosk). 2019;9:18-24.
47.
MigaczewskiMPędziwiatrMMatłokMBudzyńskiA. Laparoscopic Nissen fundoplication in the treatment of Barrett’s esophagus - 10 years of experience. Wideochir Inne Tech Maloinwazyjne. 2013;8(2):139-145.
48.
WetscherGJGadenstaetterMKlinglerPJ, et al. Efficacy of medical therapy and antireflux surgery to prevent Barrett’s metaplasia in patients with gastroesophageal reflux disease. Ann Surg. 2001;234(5):627-632.
